FDA panel votes against Novartis drug for acute heart failure Reuters (Reuters) - A drug made by Novartis AG to treat acute heart failure should not be approved because there is insufficient evidence it improves symptoms, a panel of advisers to the U.S. Food and Drug Administration concluded on Thursday. The panel's vote ... |
